These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.
192 related articles for article (PubMed ID: 11807418)
21. Recent progress in management of advanced prostate cancer. Kantoff P Oncology (Williston Park); 2005 Apr; 19(5):631-6. PubMed ID: 15945343 [TBL] [Abstract][Full Text] [Related]
22. Addition of estramustine to chemotherapy and survival of patients with castration-refractory prostate cancer: a meta-analysis of individual patient data. Fizazi K; Le Maitre A; Hudes G; Berry WR; Kelly WK; Eymard JC; Logothetis CJ; Pignon JP; Michiels S; Lancet Oncol; 2007 Nov; 8(11):994-1000. PubMed ID: 17942366 [TBL] [Abstract][Full Text] [Related]
23. Hormone refractory prostate cancer (HRPC): present and future approaches of therapy. Di Lorenzo G; De Placido S Int J Immunopathol Pharmacol; 2006; 19(1):11-34. PubMed ID: 16569343 [TBL] [Abstract][Full Text] [Related]
25. Docetaxel, low-dose estramustine, and doxifluridine in hormone-refractory metastatic prostate cancer. Wada Y; Kikuchi K; Takahashi W; Honda J; Nakanishi J; Matsumoto K; Kuwahara T; Kai N; Kikukawa H; Ueda S Cancer Chemother Pharmacol; 2008 Jan; 61(1):53-61. PubMed ID: 17375305 [TBL] [Abstract][Full Text] [Related]
26. Is there a role for platinum chemotherapy in the treatment of patients with hormone-refractory prostate cancer? Oh WK; Tay MH; Huang J Cancer; 2007 Feb; 109(3):477-86. PubMed ID: 17186531 [TBL] [Abstract][Full Text] [Related]
29. The role of chemotherapy in advanced prostate cancer. Ernst DS Can J Urol; 2002 Jun; 9 Suppl 1():21-5. PubMed ID: 12121591 [TBL] [Abstract][Full Text] [Related]
30. Phase II study of docetaxel, estramustine, and low-dose hydrocortisone in men with hormone-refractory prostate cancer: a final report of CALGB 9780. Cancer and Leukemia Group B. Savarese DM; Halabi S; Hars V; Akerley WL; Taplin ME; Godley PA; Hussain A; Small EJ; Vogelzang NJ J Clin Oncol; 2001 May; 19(9):2509-16. PubMed ID: 11331330 [TBL] [Abstract][Full Text] [Related]
31. First- and second-line chemotherapy with docetaxel or mitoxantrone in patients with hormone-refractory prostate cancer: does sequence matter? Michels J; Montemurro T; Murray N; Kollmannsberger C; Nguyen Chi K Cancer; 2006 Mar; 106(5):1041-6. PubMed ID: 16456811 [TBL] [Abstract][Full Text] [Related]
32. Combination chemotherapy with docetaxel, estramustine and suramin for hormone refractory prostate cancer. Safarinejad MR Urol Oncol; 2005; 23(2):93-101. PubMed ID: 15869993 [TBL] [Abstract][Full Text] [Related]
33. Oral estramustine and cyclophosphamide in patients with metastatic hormone refractory prostate carcinoma: a phase II study. Bracarda S; Tonato M; Rosi P; De Angelis V; Mearini E; Cesaroni S; Fornetti P; Porena M Cancer; 2000 Mar; 88(6):1438-44. PubMed ID: 10717628 [TBL] [Abstract][Full Text] [Related]
34. The current role of chemotherapy in metastatic hormone-refractory prostate cancer. Petrylak DP Urology; 2005 May; 65(5 Suppl):3-7; discussion 7-8. PubMed ID: 15885271 [TBL] [Abstract][Full Text] [Related]
35. Activity of docetaxel with or without estramustine phosphate versus mitoxantrone in androgen dependent and independent human prostate cancer xenografts. Oudard S; Legrier ME; Boyé K; Bras-Gonçalves R; De Pinieux G; De Cremoux P; Poupon MF J Urol; 2003 May; 169(5):1729-34. PubMed ID: 12686819 [TBL] [Abstract][Full Text] [Related]
36. Prednisone plus cabazitaxel or mitoxantrone for metastatic castration-resistant prostate cancer progressing after docetaxel treatment: a randomised open-label trial. de Bono JS; Oudard S; Ozguroglu M; Hansen S; Machiels JP; Kocak I; Gravis G; Bodrogi I; Mackenzie MJ; Shen L; Roessner M; Gupta S; Sartor AO; Lancet; 2010 Oct; 376(9747):1147-54. PubMed ID: 20888992 [TBL] [Abstract][Full Text] [Related]
37. Docetaxel plus prednisone versus mitoxantrone plus prednisone for metastatic hormone-refractory prostate cancer in Chinese patients: experience of a single center. Zhang HL; Ye DW; Yao XD; Dai B; Zhang SL; Shen YJ; Zhu Y; Zhang W Urol Int; 2007; 79(4):307-11. PubMed ID: 18025847 [TBL] [Abstract][Full Text] [Related]
38. Phase III trial of satraplatin, an oral platinum plus prednisone vs. prednisone alone in patients with hormone-refractory prostate cancer. Sternberg CN; Whelan P; Hetherington J; Paluchowska B; Slee PH; Vekemans K; Van Erps P; Theodore C; Koriakine O; Oliver T; Lebwohl D; Debois M; Zurlo A; Collette L; Oncology; 2005; 68(1):2-9. PubMed ID: 15741753 [TBL] [Abstract][Full Text] [Related]
39. Safety and efficacy of the MDR inhibitor Incel (biricodar, VX-710) in combination with mitoxantrone and prednisone in hormone-refractory prostate cancer. Rago RP; Einstein A; Lush R; Beer TM; Ko YJ; Henner WD; Bubley G; Merica EA; Garg V; Ette E; Harding MW; Dalton WS Cancer Chemother Pharmacol; 2003 Apr; 51(4):297-305. PubMed ID: 12721757 [TBL] [Abstract][Full Text] [Related]
40. Treatment options in hormone-refractory prostate cancer: current and future approaches. Harris KA; Reese DM Drugs; 2001; 61(15):2177-92. PubMed ID: 11772129 [TBL] [Abstract][Full Text] [Related] [Previous] [Next] [New Search]